TBC1269: Phase I data; Phase IIa

TXBI's Revotar Pharmaceuticals AG subsidiary (Berlin, Germany) said that in 2 German Phase I trials, TBC1269 showed no serious adverse events and was well tolerated. In a double-blind, single-dose Pha...